Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Antirrhinoside SCHEMBL27233579 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL422972 | 0.85 | ALDH1A1 (0.53) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL9057878 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| Harpagide SCHEMBL30132931 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| Harpagide SCHEMBL29385820 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| Harpagide SCHEMBL1425414 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL9057635 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| Sesamoside SCHEMBL26561978 | 0.75 | POLB (0.52) | MEN1KMT2APOLBCTDSP1MAPT | |
| SCHEMBL29208523 | 0.73 | ALDH1A1 (0.71) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL29425887 | 0.73 | ALDH1A1 (0.71) | ALDH1A1TSHRMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022157678-A1 | METHOD OF OBTAINING SURFACTIN-STABILISED POLY(D,L-LACTIDE) NANOCARRIERS AND NANOCARRIERS PRODUCED WITH THIS METHOD | INVENTIONBIO SPOLKA AKCYJNA (PL) | 2022-07-28 | — | — | WO | disclosed |
| US-20210330731-A1 | TOPICAL SALVE FORMULATIONS FOR DERMAL ALKALOID DELIVERY | MARTIN ROBERT L (US) | 2021-10-28 | — | — | US | disclosed |
| US-20190022159-A1 | NOVEL METHOD FOR PREPARING PURIFIED EXTRACTS OF HARPAGOPHYTUM PROCUMBENS | BURGUNDY (FR) | 2019-01-24 | — | — | US | disclosed |
| US-10111917-B2 | Method for preparing purified extracts of harpagophytum procumbens | NATUREX (FR) | 2018-10-30 | — | — | US | disclosed |
| EP-2845624-B1 | Mucoadhesive devil's claw extracts (harpagophytum procumbens) and uses thereof | ABOCA S P A SOCIETÀ AGRICOLA (IT) | 2017-06-07 | — | — | EP | disclosed |
| EP-2144620-B1 | NOVEL METHOD FOR PREPARING PURIFIED EXTRACTS OF HARPAGOPHYTUM PROCUMBENS | NATUREX (FR) | 2015-10-21 | — | — | EP | disclosed |
| EP-2845624-A1 | Mucoadhesive devil's claw extracts (harpagophytum procumbens) and uses thereof | Aboca S.p.A. Societa' Agricola (IT) | 2015-03-11 | — | — | EP | disclosed |
| US-20130337090-A1 | PLANT EXTRACTS FOR TREATING BURNS AND CHRONIC WOUNDS | SKIN MATRIX LTD. (IL) | 2013-12-19 | — | — | US | disclosed |
| EP-2635291-A1 | PLANT EXTRACTS FOR TREATING BURNS AND CHRONIC WOUNDS | Skin Matrix Ltd. (IL) | 2013-09-11 | — | — | EP | disclosed |
| US-8293315-B2 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| EP-1616489-A1 | Food additive | Cognis IP Management GmbH (DE) | 2006-01-18 | — | — | EP | disclosed |
| EP-1602364-A1 | Microcapsules (XXX) comprising plant extracts and process for their preparation | Cognis IP Management GmbH (DE) | 2005-12-07 | — | — | EP | disclosed |
| EP-1581183-A1 | CHEWING GUM COMPOSITION WITH VEGETAL ADDITIVES | Cognis IP Management GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-6812214-B2 | ADMINISTERING HARPAGIDE AND HARPAGOSIDE, OBTAINED FROM PLANT HARPAGOPHYTUM PROCUMBENS DC FOR THERAPY AND PROPHYLAXISA OF ARTHRITIS, OSTEOPOROSIS AND RUPTURED DISC | Shin, Joon Shik (KR) | 2004-11-02 | — | — | US | disclosed |
| WO-2004062639-A1 | CHEWING GUM COMPOSITION WITH VEGETAL ADDITIVES | COGNIS IP MANAGEMENT GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003103694-A1 | USE OF ACTIVE INGREDIENT MIXTURES CONTAINING TOCOPHEROLS AND EXTRACTS OF HARPAGOPYTUM PROCUMBENS FOR PRODUCING A MEDICAMENT FOR ARTHRITIS | COGNIS IBERIA S.L. (ES) | 2003-12-18 | — | — | WO | disclosed |
| EP-1371372-A1 | Use of active substance mixtures containing tocopherols and harpagophytum procumbens extracts for the preparation of a drug against rheumatic arthritis | Cognis Iberia, S.L. (ES) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183264-A1 | Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same | SHIN, JOON SHIK (KR) | 2002-12-05 | — | — | US | disclosed |
| US-6280737-B1 | DRUG EXTRACT OBTAINED BY EXTRACTING PLANT ROOTS WITH WATER OR MIXTURE OF ETHANOL AND WATER, CONCENTRATING, STIRRING WITH ALIPHATIC ALCOHOL AND/OR ALIPHATIC KETONE, SEPARATING INSOLUBLE FRACTION FROM OBTAINED SOLUBLE FRACTION | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2001-08-28 | — | — | US | disclosed |
| WO-1996010408-A1 | CARDIOACTIVE COMPOUNDS ISOLATED FROM WOODY PERENNIALS | THE EXECUTIVE DIRECTOR OF THE WESTERN AUSTRALIAN DEPARTMENT OF CONSERVATION AND LAND MANAGEMENT (AU) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183264-A1 | Use of harpagid-related compounds for prevention and treatment of osteoporosis, arthritis and ruptured disc and pharmaceutical composition containing the same | CFD, NR1D1, NR1D2 | ALDH1A1 654/4885TSHR 2377/4885MEN1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.